Vanda Pharmaceuticals Inc., of Washington, reported net product sales of $43.6 million for the first quarter. Sales of Hetlioz (tasimelteon), approved of non-24-hour sleep-wake disorder, reached $25.4 million, up 26 percent from the same period last year, while sales of antipsychotic drug Fanapt (iloperidone) totaled $18.2 million, up 5 percent over the first quarter of 2017.